Société RXi Pharmaceuticals Corp Nasdaq
Actions
US74979C8082
Recherche biotechnologique et médicale
Métier
Dirigeants
Dirigeants | Titre | Age | Depuis |
---|---|---|---|
Robert Bitterman
CEO | Chief Executive Officer | 73 | 19/06/12 |
Caitlin Kontulis
DFI | Director of Finance/CFO | - | - |
James Cardia
CTO | Chief Tech/Sci/R&D Officer | - | 15/09/17 |
Linda M. Mahoney
PRN | Corporate Officer/Principal | - | 10/11/22 |
Administrateurs
Administrateurs | Titre | Age | Depuis |
---|---|---|---|
Robert Bitterman
CEO | Chief Executive Officer | 73 | 19/06/12 |
Director/Board Member | 73 | 02/05/22 | |
Curtis Lockshin
BRD | Director/Board Member | 64 | 18/04/13 |
Jonathan Freeman
BRD | Director/Board Member | 56 | 07/06/17 |
Robert Ferrara
BRD | Director/Board Member | 73 | 01/10/19 |
Classe d'actions
Vote | Nombre | Flottant | Autocontrôle | Flottant Total | |
---|---|---|---|---|---|
Action A | 1 | 4 591 700 | 4 564 638 ( 99,41 %) | 0 | 99,41 % |
Coordonnées société
Phio Pharmaceuticals Corp.
11 Apex Drive Suite 300A PMB 2006
01752, Marlborough
+508-767-3861
http://www.phiopharma.comSecteur
Varia. 1 janv. | Capi. | |
---|---|---|
+26,37% | 44,96 Md | |
-1,01% | 42,65 Md | |
+46,00% | 41,85 Md | |
-5,31% | 29,04 Md | |
+9,34% | 26,08 Md | |
-21,69% | 19,03 Md | |
+6,23% | 12,75 Md | |
+26,99% | 12,06 Md | |
-3,38% | 11,75 Md |